Related Experiment Video
Updated: Sep 13, 2025

Bioluminescent Orthotopic Model of Pancreatic Cancer Progression
Published on: June 28, 2013
Bacteria and tumor debris induced pancreatic cancer progression via the NF-κB signaling pathway
Qi Chen1, Yonghao Xu2, Yisu Wang3
1Zhejiang Provincial Key Laboratory of Pancreatic Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China; Laboratory of Animal Research Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Abstract:
The tumor microenvironment (TME) of metastatic pancreatic ductal adenocarcinoma (PDAC) is characterized by significant cellular and spatial heterogeneity, and long-term hypoxia, leading to micronecrotic regions. PDAC clinical specimens were employed to investigate micronecrosis and we identified that bacteria and lipopolysaccharide (LPS) co-existed in PDAC tissue. Tumor-associated macrophages (TAMs) polarized by these complex components exhibit a distinct pro-inflammatory effect and correlate with drug resistance in pancreatic cancer. Single-cell data from the GEO database were used to identify differentially enrichment pathways between normal and cancer tissues. We explored the molecular mechanism of PDAC progression via macrophage-induced inflammation and immune evacuation. The bacterial components, in conjunction with PDAC debris, induced epithelial-mesenchyme transition in pancreatic cancer cells by activating nuclear factor kappa B (NF-κB) signaling and increasing programmed cell death ligand 1 (PD-L1) expression in TAMs, thus facilitating tumor progression. We then identified that CBL0137 significantly decreased PD-L1 expression by inhibiting NF-κB signaling and therapeutic efficacy was evaluated through systematic in vivo and in vitro drug experiments, Additionally, CBL0137 could synergize with gemcitabine to enhance its anti-tumor effect. Our results demonstrated the impact of necrosis and inflammation on tumor progression via TAMs and potential therapy strategies, suggesting that CBL0137 may be represented as a promising therapeutic candidate for PDAC.
Insights
Necrosis and bacteria in pancreatic cancer promote tumor growth by activating macrophages. The drug CBL0137 inhibits this pathway, showing promise as a pancreatic ductal adenocarcinoma treatment.
Area of Science:
- Oncology
- Immunology
- Microbiology
Background:
- Metastatic pancreatic ductal adenocarcinoma (PDAC) exhibits a complex tumor microenvironment (TME) with hypoxia and necrosis.
- Bacteria and lipopolysaccharide (LPS) coexist within PDAC tissues, influencing tumor progression.
Purpose of the Study:
- To investigate the role of micronecrosis, bacterial components, and tumor-associated macrophages (TAMs) in PDAC progression.
- To explore the molecular mechanisms driving PDAC via inflammation and immune evasion.
- To evaluate CBL0137 as a potential therapeutic agent for PDAC.
Main Methods:
- Analysis of PDAC clinical specimens to identify bacterial presence and LPS.
- Utilizing single-cell data from the GEO database to analyze pathway enrichment.
- In vitro and in vivo experiments to assess the efficacy of CBL0137 and its combination with gemcitabine.
Main Results:
- Bacterial components and LPS polarize TAMs, promoting inflammation and drug resistance.
- PDAC debris and bacterial components induce epithelial-mesenchymal transition (EMT) via NF-κB signaling.
- CBL0137 effectively reduces PD-L1 expression by inhibiting NF-κB signaling, demonstrating anti-tumor effects and synergy with gemcitabine.
Conclusions:
- Necrosis and inflammation, mediated by TAMs, significantly impact PDAC progression.
- CBL0137 shows potential as a therapeutic strategy for PDAC by targeting the NF-κB/PD-L1 axis.
- CBL0137 may synergize with standard chemotherapy, offering enhanced anti-tumor efficacy in PDAC treatment.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
The Tumor Microenvironment
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

